Umer Bin Abdul Aziz

Dr. Umer Bin Abdul Aziz is a researcher at the Institute of Pharmacy, part of the Department of Biology, Chemistry and Pharmacy at Freie Universität Berlin. He works under the guidance of Prof. Dr. Jörg Rademann in the field of Pharmaceutical and Medicinal Chemistry.

His research focuses on innovative drug development strategies, including molecular evolution for anticancer therapies, novel antiviral approaches, and antibiotic alternatives like pathoblockers. This work intersects with disciplines such as chemical biology, tumor cell targeting, and pharmaceutical chemistry.

The trends in his research publications highlight advancements in molecular evolution techniques for drug synthesis, tumor cell targeting, and addressing antibiotic resistance. These studies often leverage interdisciplinary methods bridging chemistry, biology, and pharmacology.

He is affiliated with the Research Group Prof. Rademann, which emphasizes pharmaceutical chemistry and medicinal chemistry. His work has been featured in prominent journals like Nature Communications, underscoring its impact in oncology and drug design.